EA200001244A1 - Комбинационная терапия для лечения биполярных расстройств - Google Patents

Комбинационная терапия для лечения биполярных расстройств

Info

Publication number
EA200001244A1
EA200001244A1 EA200001244A EA200001244A EA200001244A1 EA 200001244 A1 EA200001244 A1 EA 200001244A1 EA 200001244 A EA200001244 A EA 200001244A EA 200001244 A EA200001244 A EA 200001244A EA 200001244 A1 EA200001244 A1 EA 200001244A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
combination therapy
bipolar disorders
depression
bipolar
Prior art date
Application number
EA200001244A
Other languages
English (en)
Other versions
EA003611B1 (ru
Inventor
Гари Деннис Толлефсон
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200001244A1 publication Critical patent/EA200001244A1/ru
Publication of EA003611B1 publication Critical patent/EA003611B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Данное изобретение обеспечивает способы и композиции для лечения биполярного расстройства, биполярной депрессии или униполярной депрессии, все с психотическими признаками или без них. Этот способ предусматривает применение соединения, обладающего активностью атипичного антипсихотического средства и ингибитора повторного поглощения серотонина.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200001244A 1998-05-29 1999-05-21 Комбинационная терапия для лечения биполярных расстройств EA003611B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8712698P 1998-05-29 1998-05-29
PCT/US1999/011314 WO1999062522A1 (en) 1998-05-29 1999-05-21 Combination therapy for treatment of bipolar disorders

Publications (2)

Publication Number Publication Date
EA200001244A1 true EA200001244A1 (ru) 2001-06-25
EA003611B1 EA003611B1 (ru) 2003-06-26

Family

ID=22203275

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200001244A EA003611B1 (ru) 1998-05-29 1999-05-21 Комбинационная терапия для лечения биполярных расстройств

Country Status (19)

Country Link
EP (1) EP0966967A3 (ru)
JP (1) JP2002516864A (ru)
KR (1) KR20010043731A (ru)
CN (1) CN1302207A (ru)
AU (1) AU756468B2 (ru)
BR (1) BR9911068A (ru)
CA (1) CA2332408A1 (ru)
CZ (1) CZ20004280A3 (ru)
EA (1) EA003611B1 (ru)
HR (1) HRP20000798A2 (ru)
HU (1) HUP0102511A2 (ru)
IL (1) IL139591A0 (ru)
NO (1) NO20005884L (ru)
NZ (1) NZ507981A (ru)
PL (1) PL344304A1 (ru)
SK (1) SK17492000A3 (ru)
TR (1) TR200003525T2 (ru)
WO (1) WO1999062522A1 (ru)
ZA (1) ZA200006817B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
WO2000030648A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
FR2802101B1 (fr) * 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
AU2001280865A1 (en) 2000-08-02 2002-02-13 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
MXPA03006003A (es) 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
CA2445528A1 (en) * 2001-04-26 2002-11-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7410759B2 (en) 2002-11-01 2008-08-12 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
KR100842694B1 (ko) 2002-12-27 2008-07-01 오쓰까 세이야꾸 가부시키가이샤 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
WO2004100957A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of bipolar disorders and associated symptoms
US9125939B2 (en) * 2003-05-23 2015-09-08 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
EP1696896A2 (en) * 2003-12-15 2006-09-06 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
EP1758600A4 (en) * 2004-06-04 2008-03-05 Mood Man Sciences Llc METHOD AND COMPOSITIONS FOR TREATING MUTUAL DISORDER
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EP1766077B1 (en) 2004-06-21 2012-03-28 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
JP5366554B2 (ja) 2005-11-12 2013-12-11 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー うつを診断および処置するためのｆｇｆ２関連方法
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2007137167A2 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US20080199866A1 (en) * 2006-10-10 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University Snp detection and other methods for characterizing and treating bipolar disorder and other ailments
GB0814466D0 (en) * 2008-08-07 2008-09-10 Rosemont Pharmaceuticals Ltd Sertraline composition
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN108926569A (zh) * 2018-08-24 2018-12-04 山西医科大学第医院 一种非典型抗精神病药物组合物
CN109464436A (zh) * 2019-01-10 2019-03-15 高智玉 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用
CN110151718A (zh) * 2019-06-13 2019-08-23 厦门医学院 一种奥氮平口腔崩解片及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8072691A (en) * 1990-06-28 1992-01-23 Beecham Group Plc Pharmaceutical preparations
HUP9903679A3 (en) * 1996-03-11 2001-10-29 Lilly Co Eli Use of olanzapine for the preparation of pharmaceutical compositions treating bipolar disorder
CA2250187A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Composition comprising olanzapine and a drug useful in the treatment of pain for use in the treatment of pain
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
PL344304A1 (en) 2001-10-22
NO20005884L (no) 2001-01-24
AU756468B2 (en) 2003-01-16
HUP0102511A2 (hu) 2001-11-28
EP0966967A3 (en) 2000-05-31
HRP20000798A2 (en) 2001-10-31
NO20005884D0 (no) 2000-11-21
JP2002516864A (ja) 2002-06-11
TR200003525T2 (tr) 2001-04-20
KR20010043731A (ko) 2001-05-25
IL139591A0 (en) 2002-02-10
WO1999062522A1 (en) 1999-12-09
BR9911068A (pt) 2001-02-06
EA003611B1 (ru) 2003-06-26
ZA200006817B (en) 2002-02-21
CN1302207A (zh) 2001-07-04
EP0966967A2 (en) 1999-12-29
NZ507981A (en) 2003-10-31
SK17492000A3 (sk) 2002-04-04
CA2332408A1 (en) 1999-12-09
AU4008899A (en) 1999-12-20
CZ20004280A3 (cs) 2001-09-12

Similar Documents

Publication Publication Date Title
EA200001244A1 (ru) Комбинационная терапия для лечения биполярных расстройств
EA200000349A1 (ru) Способ лечения оппозиционного расстройства
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
EA200100588A1 (ru) Пиперидины как модуляторы ccr5
EA200400498A1 (ru) Производные фенилпиперазина как ингибиторы обратного захвата серотонина
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
DK0751939T3 (da) Naphthylamider som centralnervesystemmidler
EA199900324A1 (ru) Комбинированная терапия для лечения психозов
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
AR032086A1 (es) Combinaciones de farmacos
EA199800667A1 (ru) Новые фенантридины
EA200500856A1 (ru) Новые химические соединения
EA200001218A1 (ru) Комбинационная терапия для лечения резистентной депрессии
DE60237917D1 (de) Gfats als modifikatoren des p53-wegs und verwendungsverfahren
BR9712085A (pt) Inibidores de metaloprotease heterocìclicos
EA200500488A1 (ru) Фармацевтические составы модафинила
DE60200492D1 (de) Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen
EA200401160A1 (ru) Производные тиазола и оксазола, которые модулируют активность ppar
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
DE69931957D1 (de) Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns-erkrankungen
EA199800867A1 (ru) Соединения тетрагидробетакарболина
BR0315247A (pt) Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit
EA200200948A1 (ru) Лечение псориаза

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU